Orakl Oncology raises $34M Series A for AI-predicted cancer drug results

On November 13, 2026, The Next Web reported that Paris-based Orakl Oncology has closed a $34M Series A round, co-led by Norrsken VC and Singular. The company's approach centers on growing copies of patients' tumours in the lab, testing drugs against those copies, and then using AI to predict how clinical trials will turn out. According to the same report, the newly raised capital is intended to support an expansion into lung cancer and gastric cancer, broadening the scope of the company's work beyond its current activities. At this point, this funding event is documented by a single report, and no follow-up developments have been made public. No additional details about the round's other participants, valuation, or timeline for the planned expansion have emerged, so the story currently rests at the point of the completed Series A announcement, with further updates still pending. For now, the available record covers only the amount, the lead investors, the company's stated methodology, and the intended use of the funds.